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Abstract
Background: Eating disorders (ED) have a multifactorial aetiology in which genetics play an important role. Several 
studies have found an association between the Val66Met (G196A) polymorphism of the Brain-Derived Neurotrophic 
Factor (BDNF) and Eating disorders.
The aim of this study was to determine the association of the Val66Met (G196A) polymorphism of the BDNF gene and
its effect on eating disorders (ED), energy intake and BMI in schoolchildren.
Methods: Two-year cohort study (preadolescence to adolescence). From an initial sample of 1336 Caucasian children 
(mean age = 11.37 years), a group at risk of ED (n = 141) and a control group (n = 117) were selected using the 
Children's Eating Attitudes Test. Two years later, they were re-classified into an at-risk group (n = 41) and a control 
group (n = 159) using the Eating Attitudes Test. The diagnosis of the individuals at risk of ED was confirmed by means 
of the Diagnostic Interview for Children and Adolescents. BMI, energy intake and the Val66Met (G196A) polymorphism 
of the BDNF gene were analysed in the at-risk and control groups.
Results: The frequency of genotypes of the Val66Met (G196A) polymorphism of the BDNF gene is 28.6% (95% CI: 22.4-
34.9) in the heterozygous form (Val/Met) and 5% (95% CI: 2.4-9) in the homozygous form (Met/Met). We detected no 
association between Val66Met genotypes and the severity of ED. Over time, the carriers of the Met66 allele with a 
persistent risk of ED significantly restricted energy intake (507 Kcal/day; p = 0.033).
Conclusion: We have not found an association between Val66Met (G196A) polymorphism of the BDNF and ED in 
schoolchildren from general population. The relationship found between this polymorphism and energy intake 
restriction in adolescents with a persistent risk of ED should be replicated in a larger sample.
Background
Eating disorders (ED) have a multifactorial aetiology and
negatively affect both the psychosocial and developmen-
tal levels. A high proportion of adolescents--between 20%
and 25%--have inappropriate attitudes towards weight
control [1-3]. The continuity hypothesis of ED supported
by Vanderheyden and Boland [4] suggests that risky atti-
tudes could be responsible for ED [5,6] and may be
related to the same biological and personality characteris-
tics that are present in full-blown syndromes.
Many studies have investigated the role of genetics in
ED. Brain-derived neurotrophic factor (BDNF) is a pro-
tein belonging to the neurotrophin family that is involved
in the proliferation, differentiation and survival of neu-
rons in the nervous system [7]. In the past few years, it
has generated considerable interest because of its distri-
bution in the key brain regions that are involved in behav-
iour, energy homeostasis and weight control.
Furthermore, BDNF provides trophic support to nora-
drenergic, dopaminergic and serotonergic neurons,
among others [8], whose neurotransmitters are altered in
many mental illnesses. Some researchers have hypothe-
sised that neurotrophins are involved in mental illnesses
because of an alteration in synaptic plasticity [9,10], in
which BDNF plays a fundamental role. This synaptic
alteration could be due to the Val66Met (G196A) poly-
morphism of the BDNF gene (MIM 113505), which alters
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how the secretion of mature BDNF is regulated [11,12].
This polymorphism (Single Nucleotide Polymorphism
database (dbSNP) rs6265) is located on chromosome
11p13-11p14 [13], which encodes the peptide precursor
(proBDNF) of BDNF.
Restricting anorexia nervosa (AN) and minimum body
mass index (BMI) has been associated with the aforemen-
tioned Val66Met (G196A) polymorphism of the BDNF
gene, and it has been suggested that the A allele (Met)
may affect susceptibility to ED [14,15]. In a broad popula-
tion from six samples in five European countries, consist-
ing mainly of women aged 20-30, the association of the
polymorphism was extended to all kinds of ED, including
restricting AN (ANR), binge-eating AN (ANB) and buli-
mia nervosa (BN) [14]. In Japan, Koizumi et al [16]
observed significant differences between the genotypes of
the Val66Met (G196A) polymorphism in female patients
with ED (EDNOS, AN and BN) and those of control par-
ticipants. When observed separately, however, significant
differences were found only in the distribution of geno-
types in ANR and purging BN. A significant association
was also found between a higher score on the Bulimic
Investigatory Test, Edinburgh (BITE) and the AA geno-
type (Met/Met) in patients with BN and binge ED [17].
A recent meta-analysis study [18] suggested that Cau-
casian individuals aged 20-26 with Val/Met genotypes
have a 36% higher risk of developing ED than those with
the Val/Val genotype. However, some studies have found
there to be no association in patients with ED [17,19,20].
BDNF is also known to play a key role in eating behav-
iour and weight regulation [21]. Both BDNF and its
receptor NTRK2 are found in hypothalamic areas that are
critical to feeding and energy regulation [22]. Studies car-
ried out on animals suggest that hyperphagia affects not
only the relationship between the level of BDNF and BMI
[23], but also the regulation of food intake by acting as an
anorexigenic factor [24,25].
Attempts have been made to establish an association
between polymorphism and BMI in the general adult
population of both sexes, but the results are contradic-
tory. Compared with the Val/Met and Val/Val genotypes,
the association between the Met/Met genotype and low
BMI is much greater [26]. Nevertheless, contrary to the
results of a recent study [27], we observed that patients
with BN carrying the Met66 allele of the BDNF gene and
the 7R allele of the dopamine-4 receptor gene (DRD4)
have a higher BMI. Mutations in the gene that encodes
the BDNF or its receptor (TrKB) may explain certain
kinds of obesity or forms of ED in humans [25].
In light of the lack of research on the frequency of
BDNF gene alteration in the adolescent population, the
contradictory results reported to date with regard to the
association between BDNF gene alteration and ED, and
the main consequences of this type of alteration on
energy intake and BMI, we decided to undertake a longi-
tudinal study to clarify these aspects. The objectives of
our study were: a) to determine the relation between the
frequency of the Val66Met (G196A) polymorphism of the
BDNF gene and the severity of risk of ED, b) to establish
the association between genetic alteration and risk of ED,
and c) to study the effects of this genetic alteration on
BMI and energy intake according to the evolution of the
risk of ED.
Methods
Design
Two-year cohort study.
Participants
We studied 258 Spanish schoolchildren of Caucasian ori-
gin of both sexes aged 10-13 (mean = 11.37, SD = 0.62)
taken from an initial sample of 1,336 schoolchildren (649
boys and 687 girls). The participants were taken from 17
randomly selected primary schools so that the group was
representative of the social and cultural backgrounds of
various places (cities and suburbs) within the province of
Tarragona (Spain). This sample was studied in two
phases. In the first phase of the study, an ED screening
test (Children's Eating Attitudes Test, or ChEAT) was
administered to the entire sample in order to select at-
risk schoolchildren. A total of 141 were included in the
at-risk group and 117 were included in the control group;
the ages of the children ranged from 11 to 13 (mean =
11.31, SD = 0.59). In the preadolescent stage of the sec-
ond phase, controls were randomly selected from those
whose score on the ChEAT was at or below the cut-off
and whose characteristics of age, gender and type of
school were similar. Two years later, in the adolescent
stage, the individuals in the sample from the second
phase, now aged 13-15 (mean = 13.79, SD = 0.72) were
assessed once again. Of these individuals, a total of 113
at-risk individuals and 87 controls were identified. These
subjects were given the Eating Attitudes Test (EAT), and
41 were found to be at risk and 159 were selected as con-
trols. Figure 1 gives a description of the sample. For fur-
ther information, see Canals F, et al. (in press) and Sancho
C et al [28].
The reasons for non-participation were lack of parental
consent, absence from school or refusal by the potential
subject. The percentages of participation were 87.8% in
the screening phase and 88.97% in the preadolescent
stage. Of these, 77.52% were monitored in the adolescent
stage.
Procedure
Before starting the study, we obtained permission from
the Catalan Government and from the schools' headmas-
ters. Informed consent was also obtained from the chil-Arija et al. BMC Public Health 2010, 10:363
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dren's parents in both phases of the study. The study was
approved by the Ethics Committee for Clinical Research
at the Sant Joan University Hospital in Reus (Spain).
In the first stage of the study, the preadolescent partici-
pants in the initial sample took the adapted ChEAT [29]
in the classroom while the researchers (a psychologist
and a dietician) were present. We took a sample of the
participants who scored at least 17 (the ChEAT cut-off
score) and a control group of participants who scored
below the cut-off by selecting two out of every three
cases. The at-risk participants and controls were weighed
and measured, and their BMIs calculated. Their energy
intake was assessed by their parents with a three-day food
record for two non-consecutive weekdays and one week-
end day (and confirmed by the children with a photo-
graph album of dishes and portions). The ED section of
the Diagnostic Interview for Children and Adolescents
(children's version, DICA-C) was used to make individual
assessments.
Two years later, we phoned the families that had partic-
ipated in the preadolescent stage to inform them that the
adolescent stage of the study was to be held. Individuals
who agreed to participate again were assessed using the
EAT [30] and were weighed and measured so that their
BMIs could be calculated. In this stage we used the EAT
because it is a reliable test for adolescents but not for chil-
Figure 1 Description of the sample. ChEAT: Children's Eating Attitudes Test; DICA-C: Diagnostic Interview for Children and Adolescents, children's 
version; EAT: Eating Attitudes Test; DICA-A: Diagnostic Interview for Children and Adolescents, adolescents' version. Data published by Sancho et al 
[28].
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dren. Participants were also assessed individually using
the ED section of the Diagnostic Interview for Children
and Adolescents (adolescents' version, DICA-A). Energy
intake was assessed by means of a 24-hour recall inter-
view for three non-consecutive days, including one which
was not a weekday. We collected samples of oral epithe-
lium so that we could subsequently analyze the Val66Met
polymorphism of the BDNF gene. We used double-blind
evaluation methods in both phases.
We classified the participants into four groups defined
by the evolution of the risk of ED according to the results
of the ChEAT and the EAT: A) no risk in either stage
(NoTNo); B) risk in the first stage but not in the second
stage (YesTNo); C) no risk in the first stage but risk in the
second stage (NoTYes); and D) risk in both the first and
second stages (YesTYes). These groups were checked
using the DICA-C and the DICA-A in order to eliminate
false controls, which accounted for 3.4% in the preadoles-
cent stage and 13.2% in the adolescent stage. We classi-
fied participants into four groups in order to study the
evolution of ED according to the DICA-C (preadolescent
stage) and the DICA-A (adolescent stage). We considered
individuals with subclinical syndromes, EDNOS and full
syndromes as part of the ED diagnostic group [28].
We used DSM-IV criteria to define the cases of EDNOS
and subclinical syndromes on the basis of information
collected with the DICA-C and the DICA-A. We defined
participants with subclinical anorexia as those who fulfil
the psychopathological criteria of ED based on fear of
gaining weight (B criteria for AN) or self-esteem that is
completely based on body weight and shape (C criteria
for AN), but who do not satisfy clinical criteria such as
amenorrhea (D criteria for AN) or weight loss (A criteria
for AN). For subclinical bulimia, we did not consider the
frequency of binge eating (C criteria for BN) or the loss of
control over eating during the episode (A-2 criteria for
BN).
Instruments
Assessment of risk of ED and diagnoses
Children's Eating Attitudes Test (ChEAT) [31]
This 26-item scale is designed to assess maladaptive or
problematic eating attitudes and behaviours among chil-
dren. In this study, we used a 20-item experimental
adapted Spanish version (reliability α = 0.73) to detect
possible risk of ED and used a cut-off score of 17 [29].
Eating Attitudes Test (EAT) [32]
This 40-item self-report has six possible answers and is
designed to assess ED behaviours. It has good psycho-
metric characteristics of reliability and validity. In this
study, we administered the Spanish validated version of
the EAT (internal consistency α = 0.93) [30]. We used a
cut-off score of 25 or more because it has been shown to
provide better data on the sensitivity (87.5%) and speci-
ficity (93.9%) of young populations [33].
Diagnostic Interview for Children and Adolescents (DICA)
The Spanish computerised adaptations [34] of the DICA-
R (Diagnostic Interview for Children and Adolescents,
Revised) and the DICA-IV [35,36] were administered to
diagnose ED. The DICA is a semi structured interview for
children (DICA-C) and adolescents (DICA-A) that fol-
lows DSM-IV diagnostic criteria [37]. Although the
DICA covers several psychiatric diagnostic areas, in this
study we only administered the ED diagnostic area, which
covers AN and BN. The Kappa statistics for the test-retest
reliability of the Spanish version for ED were between
0.74 and 1.0 [34]. We made diagnoses on the basis of
information obtained with the DICA-C in the first (pre-
adolescent) stage and with the DICA-A in the second
(adolescent) stage.
Anthropometric measurements and assessment of energy 
intake
Food consumption was assessed quantitatively over the
course of three non-consecutive days, one of which was
not a weekday. Because adolescents are more aware than
preadolescents of the food they have consumed and of
family consumption habits, we used a different method
for assessing food consumption that was better adapted
to their characteristics and gave better results. In the pre-
adolescent stage, we used a food record [38], whereas in
the adolescent stage we used a 24-hour recall method
[39,40].
Food record
The parents or guardians of preadolescents recorded the
quantity of food and drink consumed by their children.
They expressed these quantities using simple measure-
ments and gave information about how the food was pre-
pared, what ingredients were used and at what time their
children ate. The data were checked in a meeting with the
parents and subsequently with the child. Particular care
was taken to determine food intake outside of the home.
This method was carried out by trained nutritionists.
24-hour recall
This method involved interviewing the adolescents. An
extensive collection of photographs with a variety of por-
tion sizes was used to provide a better assessment of the
food intake. The interviews were carried out by trained
nutritionists.
In both phases, energy intake was calculated using the
French REGAL food composition table [41], and the
Spanish food composition table [42] was used for foods
specific to Spain.
Anthropometric assessment
The BMI was calculated by dividing the participants'
weight in kilograms by their size in square metres (kg/
m2). Height was measured using an ordinary tape mea-Arija et al. BMC Public Health 2010, 10:363
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sure, with the participants standing upright and wearing
no shoes or headwear. We checked that all participants
remained still, with their heels in line with the longitudi-
nal axes of both feet. Weight was calculated using a digi-
tal scale (Tanita 305) equipped with an impedance
analyzer. The participants were weighed in the morning,
before their morning break at school. They had to wear as
little clothing as possible and go barefoot in order to pre-
vent interference with the bio impedance.
DNA extraction and genotyping
We collected samples of oral epithelium using sterilised
swabs after the children had not eaten or drunk anything
for at least 30 minutes. The samples were kept at room
temperature on specimen collection cards (S&S 903®,
Schleicher & Schuell BioScience Inc., Keene, NH, USA)
and stored in individual bags with a packet of desiccant.
The genomic DNA was extracted using isolation
reagents from a Puregene kit (Gentra Systems, USA). In
samples in which little DNA was extracted or the DNA
was weak, the entire genomic DNA was amplified using a
GenomiPhi kit (GE Healthcare, USA). The DNA was
extracted and amplified at the BioBank of the Institute for
Health Sciences Research (IRCIS) at Sant Joan University
Hospital in Reus (Spain). In one case, the DNA extraction
was not satisfactory.
The G196A variant of the BDNF gene was genotyped
using the polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) technique. The SNP
in the BDNF gene was categorised for each DNA sample
using a PCR with a total volume of 10 μl, consisting of 20
ng of DNA, H2O, 1× gold buffer (GeneAmp® gold buffer,
Applied Bio systems), 1.5 mM MgCl2, 0.2 mM dNTPs, 0.5
μM BDNF-F (5'-AGGTGAGAAGAGTGATGACC-3'),
0.5 μM BDNF-R (5'-CTGGACGTGTACAAGTCTGC-3')
and 0.5 U Taq  DNA polymerase (AmpliTaq® gold DNA
polymerase, Applied Bio systems). The initial conditions
of the PCR were 94°C for 5 min followed by 32 cycles of
30 s at 94°C, 30 s at 58°C and 30 s at 72°C, and finally 7
min at 74°C, until a 292 bp product was obtained. Diges-
tion was then carried out using the NlaIII  restriction
enzyme. For an enzyme volume of 2 μl, it contained 1×
NE buffer 4, 1 U NlaIII and H2O. Digestion was carried
out at 37°C for 1 h 15 min. Digestion with NlaIII pro-
duced four fragments with 160, 59, 58 and 15 bp, respec-
tively, in the presence of the Met66 allele, and five
fragments with 83, 77, 59, 58 and 15 bp, respectively, in
the presence of the Val66 allele. Finally, electrophoresis
was applied to a polyacrylamide gel at 12% with a TBE
buffer.
The genotyping was undertaken by the IRCIS UniLab
at the Sant Joan University Hospital in Reus (Spain).
Statistical analysis
The categorical variables have been presented as percent-
ages and their corresponding confidence interval, and the
quantitative variables (BMI and energy intake) as the
median and the interquartile range because of its skewed
distribution.
The genotypes were stratified by the severity of ED risk.
The genotype distribution at different severities of ED
risk was tested for Hardy-Weinberg equilibrium by chi-
square test or Fisher's exact test when necessary. Mann-
Whitney U test, with Bonferroni correction to solve the
multiple testing problems, were used to compare BMI
and Energy intake in the different groups. Wilcoxon test
were used to observe the relationship between genotype
and repeated measures of BMI and energy intake in the
same subjects. All data were analyzed using the SPSS
package for Windows (version 17.0). The level of statisti-
cal significance was set at p < 0.05.
Results
The frequency of the genotypes of the Val66Met (G196A)
polymorphism of the BDNF gene does not depend on the
severity of ED risk in girls (χ2 = 2.96; d.f. = 4; p = 0.562) or
in boys (χ2 = 6.25; d.f. = 4; p = 0.181) (Table 1).
Table 2 shows the distribution of the genotypes of the
polymorphism according to the evolution of risk and
diagnosis of ED in both sexes. No statistically significant
differences were found between the groups for the evolu-
tion of risk (χ2 = 6.44; d.f. = 6; p = 0.381) or of ED diagno-
sis (χ2 = 3.097; d.f. = 6; p = 0.797).
The distribution of genotypes according to the severity
of ED did not differ significantly from that expected from
the Hardy-Weinberg equilibrium in the control group (χ2
= 0.06; d.f. = 2; p = 0.970) (χ2 = 5.37-3; d.f. = 2; p = 0.977),
the risk group (χ2 = 3.48-3; d.f. = 2; p = 0.998) (χ2 = 0.04; d.f
= 2; p = 0.981) or the ED diagnosis group (χ2 = 0.04; d.f. =
2; p = 0.980) (χ2 = 0.45; d.f. = 2; p = 0.798) in girls or boys,
respectively. Nor was the genotype distribution signifi-
cantly different in the groups classified according to evo-
lution of risk and evolution of ED.
Table 3 shows the energy intake and BMI for both sexes
in the two phases of the study and compares the control
group, risk group and diagnostic group. The BMI is
higher where there is a higher level of severity of ED.
There are significant differences between the control
group and the diagnostic group in preadolescent and ado-
lescent females (p < 0.001 and 0.012 respectively) and in
preadolescent and adolescent males (p < 0.001 and 0.012
respectively). In the at-risk and diagnosis groups, how-
ever, energy intake is lower, especially in adolescent girls,
and there is a statistically significant difference between
the control group and the diagnostic group (p = 0.003).
Table 4 shows the energy intake and BMI for the groups
based on evolution of risk of ED and the gene polymor-
phism in both sexes. Significant differences were found
between the evolution in the BMIs of carriers of the Met
allele (Val/Met, Met/Met) and of carriers of the wild allele
(Val/Val) in all the groups. Significant differences inArija et al. BMC Public Health 2010, 10:363
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energy intake were found in the carriers of the Met allele
(p = 0.033) only in the YesTYes risk group (Figure 2).
In the groups based on the evolution of ED diagnosis,
no significant differences were observed in either energy
intake or BMI (data not shown in the table).
Discussion
In this study, we analysed a genetic component, the
Val66Met (G196A) polymorphism of the BDNF gene, in a
sample of schoolchildren susceptible to developing some
kind of ED. The longitudinal design allowed us to observe
the evolution of risk of ED and how it is associated with
the genotypes of the polymorphism. The frequency of the
polymorphism in our sample contributes to the intrapop-
ulation differences in Val66Met in the Caucasian popula-
tion. According to Shimizu et al., the distribution of
genotypes varies according to population: participants of
Asian origin carry a higher percentage of the Met66 allele
than participants of Caucasian origin [43].
Our results do not reveal any association between the
Val66Met (G196A) polymorphism of the BDNF gene and
the different levels of severity of risk of ED, the evolution
of risk, or ED diagnosis. These results support those
obtained for clinical populations of participants diag-
nosed with BN [17,20] and AN [19,20]. However, they
contradict the positive results obtained by Ribasés et al.
[14,15,44] and Koizumi et al. [16] for all kinds of ED.
According to various studies, the prevalence of
heterozygote (Val/Met) in AN is about 35.8%, with values
ranging from 24.4% to 45.9%, while the prevalence of
homozygote (Met/Met) is 3.6% (2.3-4.9%) [20,44]. In BN,
the average prevalence of the heterozygote is 34.8% (26.9-
42.4%) and the average prevalence of the homozygote is
5.2% (2.2-10.3%) [17,19,20]. In the control participants
who took part in the above studies, the average preva-
lence of the heterozygote was 31.9% (28.4-34.4%) and the
average prevalence of the homozygote was 3% (1.0-4.9%)
[17,19,20]. In our study, we did not observe higher per-
centages of the Met allele at higher severities of risk of
ED. Although there were no significant differences, a
higher percentage of the Met allele was found among
those schoolchildren who evolved from 'no risk' to 'at
risk', which suggests susceptibility to ED [14,15,18,44].
Therefore, the association found between individuals car-
rying the Met allele who continued to be at risk of ED and
their high restriction of energy intake (546 kcal/day) was
important. The method used to measure intake has been
validated internationally by epidemiologic studies
[38,39,45].
As in other studies on ED [17,19,20], we did not find a
relationship between Val66Met and BMI. Nevertheless,
according to the results in table 3, the girls at risk of ED or
with ED in preadolescence and adolescence were over-
weight and were dieting in adolescence. This may lead to
lower BMI in the long term. However, in our sample [46],
the most frequent diagnoses were not full-blown syn-
dromes and there was no AN diagnosis. For this reason,
and because of the early age of the participants, we
observed no reduction in the BMI. However , as can be
seen in table 4, only the Met allele carriers within the Yes-
Yes risk group restricted their energy intake. Although
this low intake may be due to under reporting, by using
the Goldberg technique we found that these girls may
really be restricting their intake [45]. Genetic factors,
then, may interact with such variables as BMI, dieting,
body dissatisfaction, and socio-cultural and emotional
factors to increase the risk of ED [47]. In contrast, an
association has been found between the Met allele and
Table 1: Frequency of the Val66Met (G196A) genotypes according to the risk of ED in preadolescence
ED severity Val/Vala Val/Metb Met/Metc p-value p-value a 
vs b+c
n % (95% CI) n % (95% CI) n % (95% CI)
Risk 32 76.2 (60.6-87.9) 9 21.4 (10.3-36.8) 1 2.4 (0.0-12.6)
Male Diagnosis 7 43.8 (19.8-70.1) 7 43.8 (19.8-70.1) 2 12.5 (1.6-38.3) 0.181 0.099
Control 22 64.7 (46.5-80.3) 9 2 6.5 (12.9-44.4) 3 8.8 (1.9-23.7)
Risk 28 68.3 (51.9-81.9) 12 29.3 (16.1-45.5) 1 2.4 (0.1-12.9)
Female Diagnosis 17 73.9 (51.6-89.8) 6 26.1 (10.2-48.4) 0 - 0.562 0.527
Control 25 61.0 (44.5-75.8) 13 31.7 (18.1-48.1) 3 7.3 (1.5-19.9)
Risk 60 72.3 (61.4-81.5) 21 25.3 (16.4-36.0) 2 2.4 (0.3-8.4)
All Diagnosis 24 61.5 (44.6-76.6) 13 33.3 (19.1-50.2) 2 5.1 (0.6-17.3) 0.433 0.199
Control 47 62.7 (50.7-73.6) 22 29.3 (19.4-41.0) 6 8.0 (3.0-16.6)
CI: Confidence interval, Diagnosis: any diagnosisA
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Table 2: Distribution of the Val66Met (G196A) genotypes according to the longitudinal evolution of the risk and diagnosis of ED
Evolution of risk Evolution of diagnosis
Val/Vala Val/Metb Met/Metc Val/Vala Val/Metb Met/Metc
n
% (95% CI)
n
% (95% CI)
n
% (95% CI)
p-value p-value a vs b+c n
% (95% CI)
n
% (95% CI)
n
% (95% CI)
p-value p-value a 
vs b+c
NoTNo 42
66.7 (53.7-78.0)
16
25.4 (15.3-37.9)
5
7.9 (2.6-17.6)
89
68.5 (60.5-76.4)
35
26.9 (19.3-34.5)
6
4.6 (1.7-9.8)
YesTNo 49
66.2 (54.3-76.8)
23
31.1 (20.8-42.9)
2
2.7 (0.3-9.4)
0.381 0.343 9
50.0 (26.0-74.0)
8
44.4 (21.5-69.2)
1
5.6 (0.1-27.3)
0.797 0.298
NoTYes 5
41.7 (15.2-72.3)
6
50.0 (21.1-78.9)
1
8.3 (0.2-38.5)
18
64.3 (44.1-81.4)
8
28.6 (13.2-48.7)
2
7.1 (0.9-23.5)
YesTYes 35
72.9 (58.2-84.7)
11
22.9 (12.0-37.3)
2
4.2 (0.5-14.3)
15
71.4 (47.8-88.7)
5
23.8 (8.2-47.2)
1
4.8 (0.1-23.8)
CI: confidence interval; NoTNo: no risk/diagnosis in either preadolescence or adolescence; YesTNo: risk/diagnosis in preadolescence but no risk/diagnosis in adolescence; NoTYes: no risk/diagnosis 
in preadolescence but risk/diagnosis in adolescence; YesTYes: risk/diagnosis in both preadolescence and adolescence.A
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Table 3: Energy intake and BMI according to the severity of the ED in preadolescence and in adolescence
Females Males
Preadolescence Adolescence p-value Preadolescence Adolescence p-value
n Median(IQR) n Median(IQR) n Median(IQR) n Median(IQR)
Controla 37 2305(678) 50 2266(804) 0.216 30 2601(650) 68 2610(1194) 0.347
Riskb 38 2193(599) 9 1871(780) 0.079 36 2554(734) 2 1913(-) 0.191
Energy intake (Kcal/day) Diagnosisc 20 2070(617) 36 1621(745) 0.058 10 2468(963) 6 2267(946) 0.588
p-valuea-b 0.203 0.15 0.807 0.225
adjusted p-valuea-b 0.406 0.3 1 0.45
p-valuea-c 0.032 0.003 0.656 0.137
adjusted p-valuea-c 0.064 0.006 1 0.274
BMI (kg/m2) Controla 36 18.6(4.2) 50 20.5(5) 0.001 30 14.3(3.9) 68 20.2(5) 0.002
Riskb 38 19.9(5.3) 9 24.9(11) 0.027 35 19.5(4.5) 2 23.9(-) 0.077
Diagnosisc 20 23.7(5.3) 36 23.5(6) 0.758 10 22.7(1.9) 6 24.5(3) 0.039
p-valuea-b 0.016 0.007 0.276 0.174
adjusted p-valuea-b 0.032 0.14 0.552 0.348
p-valuea-c <0.001 0.006 <0.001 0.006
adjusted p-valuea-c <0.001 0.012 <0.001 0.012
IQR: Interquartil range; adj.:adjusted; Diagnosis: any diagnosis; The adjusted p-value were corrected with the Bonferroni test (post-hoc comparisons between the 2 groups).Arija et al. BMC Public Health 2010, 10:363
http://www.biomedcentral.com/1471-2458/10/363
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low BMI in both the adult clinical ED population [15],
and more specifically in the ANR population [14], and the
healthy adult population, in which the Met/Met genotype
is associated with low BMI [26]. This leads us to hypothe-
sise that the lack of a significant association in our study
may be due to such factors as the age of the participants,
the small sample size of each group based on the evolu-
tion and severity of ED, and the fact that our cases are less
severe than those in the general population. The sex of
the participants was also an important factor, since most
Figure 2 Energy intake in persistent risk of ED group according to the Val66Met (G196A) genotypes. V/V: Val/Val; V/M: Val/Met; M/M: Met/Met.
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Table 4: BMI and energy intake in the groups of evolution of risk of ED according to the Val66Met (G196A) genotypes
BMI (kg/m2) Energy intake (Kcal/day)
n Preadolescence
Median(IQR)
Adolescence
Median(IQR)
p-value Preadolescence
Median(IQR)
Adolescence
Median(IQR)
p-value
NoTNo V/V 36 18.4(4.2) 20.5(5) <0.001 2357(717) 2659(1340) 0.102
V/M + M/M 21 18.4(4.3) 21(6) <0.001 2418(682) 2448(871) 0.274
YesTNo V/V 41 19.4(5.4) 21.3(6) <0.001 2300(689) 2311(1102) 0.750
V/M + M/M 20 20.7(5.4) 20.9(5) 0.02 2623(761) 2477(861) 0.277
NoTYes V/V 4 18.4(3) 22.1(2) 0.043 2120(1522) 2127(541) 0.686
V/M + M/M 6 20.4(4.7) 22.6(6) 0.028 2431(870) 1794(650) 0.075
YesTYes V/V 31 22.9(5.3) 24.7(8) 0.001 2034(670) 1762(1137) 0.387
V/M + M/M 11 22.9(4.6) 24.6(5) 0.016 2270(771) 1763(490) 0.033
IQR: Interqualtin range; NoTNo: no risk of ED in either preadolescence or adolescence; YesTNo: risk in preadolescence but no risk in adolescence;
NoTYes: no risk in preadolescence but risk in adolescence; YesTYes: risk in both preadolescence and adolescence; V/V: Val/Val; V/M: Val/Met;
M/M: Met/Met. No significant differences between V/V and V/M + M/M genotypes in either groupArija et al. BMC Public Health 2010, 10:363
http://www.biomedcentral.com/1471-2458/10/363
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clinical cases are women, whereas our study assessed
both sexes. The reason why the polymorphism did not
act in the age groups studied, then, may be that the par-
ticipants had not reached neurodevelopmental maturity.
We must also take into account that there were interac-
tions between the Val66Met and other, unstudied genetic
factors [48]. Kaplan et al. (2008) observed that interaction
between the Met66 allele of the BDNF gene and the 7R
allele of the dopamine-4 receptor gene (DRD4) is associ-
ated with a higher BMI in patients with BN. However,
when they analysed V al66Met alone, they found that it
had no effect on BMI. They hypothesized that the inter-
action of hypofunctional alleles increases intake, because
of higher levels of circulating dopamine or low levels of
BDNF, which results in a high BMI. Our results, however,
did not show a higher energy intake in participants carry-
ing the Met66 allele who were still at risk of ED in the fol-
low-up and had a high BMI. This suggests that it is the
B M I  t h a t  t r i g g e r s  t h e  o n s e t  o f  E D  b e c a u s e  i t  a f f e c t s
energy intake, particularly in carriers of the Val66Met
polymorphism.
Although we observed no direct effect of the Val66Met
polymorphism on those schoolchildren with some kind
of ED, some previous studies [49,50] have established an
indirect relationship between Val66Met and ED through
personality traits. Sen et al. [50] associated the Val/Val
genotype with neuroticism in Caucasians, specifically
with the traits of anxiety, depression, self-consciousness,
vulnerability and feelings. In Japanese women, the Met/
Met genotype was associated with higher scores on the
'reward dependence' trait in the Temperament and Char-
acter Inventory (TCI) and on the 'extraversion' trait in the
NEO Personality Inventory [49].
Conclusions
A high percentage of the general population studied was
shown to have the Val66Met (G196A) polymorphism of
the BDNF gene (33.7%; 95% CI: 27.1-40.2). However, no
direct relationship was observed between the presence of
the polymorphism and risk of ED. Nevertheless, in one
small group (adolescents with a persistent risk of ED for
at least two years), the presence of the polymorphism
leads to a greater restriction of energy intake (507 Kcal/
day, p = 0.033) than that found in the general population.
No direct relationship was found between BMI and the
polymorphism. Nevertheless, further studies with larger
samples and long-term monitoring are required if the
evolution of ED is to be better understood.
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